Castle Biosciences, Inc.
CSTL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $590 | $573 | $750 |
| - Cash | $86 | $82 | $90 | $120 |
| + Debt | $36 | $37 | $26 | $26 |
| Enterprise Value | – | $546 | $509 | $656 |
| Revenue | $83 | $86 | $88 | $86 |
| % Growth | -3.6% | -2% | 1.9% | – |
| Gross Profit | $64 | $69 | $72 | $70 |
| % Margin | 77.5% | 79.5% | 81.4% | 81.3% |
| EBITDA | $5 | $3 | $4 | $14 |
| % Margin | 6.3% | 3.8% | 4% | 15.9% |
| Net Income | -$1 | $5 | -$26 | $10 |
| % Margin | -0.6% | 5.2% | -29.4% | 11.1% |
| EPS Diluted | -0.02 | 0.15 | -0.9 | 0.32 |
| % Growth | -113.3% | 116.7% | -381.3% | – |
| Operating Cash Flow | $23 | $21 | -$6 | $24 |
| Capital Expenditures | -$15 | -$9 | -$5 | -$8 |
| Free Cash Flow | $8 | $12 | -$11 | $17 |